相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Evaluation of Exposure Change of Nonrenally Eliminated Drugs in Patients With Chronic Kidney Disease Using Physiologically Based Pharmacokinetic Modeling and Simulation
Ping Zhao et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Malcolm Rowland et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 51, 2011 (2011)
Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review
P. Zhao et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban
Mark Jean Gnoth et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Modeling and predicting drug pharmacokinetics in patients with renal impairment
Karen Rowland Yeo et al.
Expert Review of Clinical Pharmacology (2011)
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor
Dagmar Kubitza et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Confidence Assessment of the Simcyp Time-Based Approach and a Static Mathematical Model in Predicting Clinical Drug-Drug Interactions for Mechanism-Based CYP3A Inhibitors
Ying-Hong Wang
DRUG METABOLISM AND DISPOSITION (2010)
Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut-The effect of diltiazem on the time-course of exposure to triazolam
Karen Rowland Yeo et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2010)
Prediction of Human Drug-Drug Interactions from Time-Dependent Inactivation of CYP3A4 in Primary Hepatocytes Using a Population-Based Simulator
Lilly Xu et al.
DRUG METABOLISM AND DISPOSITION (2009)
Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans
C. Weinz et al.
DRUG METABOLISM AND DISPOSITION (2009)
In Vitro Metabolism of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Liver Microsomes and Hepatocytes of Rats, Dogs, and Humans
D. Lang et al.
DRUG METABOLISM AND DISPOSITION (2009)
A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of 'Bottom-Up' vs 'Top-Down' Recognition of Covariates
Masoud Jamei et al.
DRUG METABOLISM AND PHARMACOKINETICS (2009)
The Simcyp® Population-based ADME Simulator
Masoud Jamei et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2009)
Emerging evidence of the impact of kidney disease on drug metabolism and transport
T. D. Nolin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects
Dagmar Kubitza et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Altered nonrenal drug clearance in ESRD
Thomas D. Nolin
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2008)
The effect of chronic renal failure on drug metabolism and transport
Albert W. Dreisbach et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2008)
Rivaroxaban (BAY 59-7939) - an oral, direct Factor Xa inhibitor - has no clinically relevant interaction with naproxen
Dagmar Kubitza et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Simulation and prediction of in vivo drug metabolism in human populations from in vitro data
Amin Rostami-Hodjegan et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Role of P-glycoprotein inhibition for drug interactions: Evidence from in vitro and pharmacoepidemiological studies
Sonja Eberl et al.
CLINICAL PHARMACOKINETICS (2007)
Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (Rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects
D Kubitza et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects
D Kubitza et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
D Kubitza et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
The effects of dose staggering on metabolic drug-drug interactions
JS Yang et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2003)
Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4
S Kanamitsu et al.
PHARMACEUTICAL RESEARCH (2000)
分享论文
